Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 6/2014

01.06.2014 | Research Article

NFKB1 -94 insertion/deletion polymorphism and cancer risk: a meta-analysis

verfasst von: Linlin Xu, Shaoyi Huang, Wei Chen, Zhichun Song, Shu Cai

Erschienen in: Tumor Biology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Previous studies on the associations of the NFKB1 -94 insertion/deletion polymorphism with cancer risk have produced conflicting results. The purpose of this meta-analysis is to define the effect of the NFKB1 -94 insertion/deletion polymorphism on cancer risk. A search of the literature by PubMed was performed to identify studies based on the predetermined inclusion criteria. Twenty-three studies consisting of 6,494 cases and 9,884 controls were identified and analyzed. Overall, significant association was observed between the polymorphism and cancer risk under all genetic models. Subgroup analysis according to ethnicity and cancer type also detected significant association. The NFKB1 -94 insertion/deletion polymorphism was associated with cancer risk in Asian population (dominant model: OR = 1.52, 95 % CI = 1.17–1.98; recessive model: OR = 1.50, 95 % CI = 1.26–1.79; II vs. DD: OR = 1.90, 95 % CI = 1.37–2.65; ID vs. DD: OR = 1.32, 95 % CI = 1.05–1.66; I vs. D: OR = 1.37, 95 % CI = 1.17–1.60), but not in Caucasian population. In addition, significant associations in OC, HCC, and OSCC were observed, but significant associations were not found in BC and LC. The current meta-analysis suggested that NFKB1 -94 insertion/deletion polymorphism may influence cancer risk in Asian population.
Literatur
1.
Yaghoobi M, Rakhshani N, Sadr F, Bijarchi R, Joshaghani Y, et al. Hereditary risk factors for the development of gastric cancer in younger patients. BMC Gastroenterol. 2004;4:28.PubMedCentralCrossRefPubMed
2.
Berlau J, Glei M, Pool-Zobel BL. Colon cancer risk factors from nutrition. Anal Bioanal Chem. 2004;378:737–43.CrossRefPubMed
3.
Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep. 2012;32:1–15.CrossRefPubMed
4.
Song L, Li J, Zhang D, Liu ZG, Ye J, Zhan Q, et al. IKKβ programs to turn on the GADD45α-MKK4-JNK apoptotic cascade specifically via p50 NFkB1 in arsenite response. J Cell Biol. 2006;175:607–17.PubMedCentralCrossRefPubMed
5.
Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002;109:81–96.CrossRef
6.
Solan NJ, Miyoshi H, Carmona EM, Bren GD, Paya CV. RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem. 2002;277:1405–18.CrossRefPubMed
7.
Giefing M, Wierzbicka M, Rydzanicz M, Cegla R, Kujawski M, et al. Chromosomal gains and losses indicate oncogene and tumor suppressor gene candidates in salivary gland tumors. Neoplasma. 2008;55:55–60.PubMed
8.
Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35–45.CrossRefPubMed
9.
Zhang P, Wei Q, Li X, Wang K, Zeng H, Bu H, et al. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet. 2009;191:73–7.CrossRefPubMed
10.
Cheng CW, Su JL, Lin CW, Su CW, Shih CH, Yang SF, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS One. 2013;8:e56130.PubMedCentralCrossRefPubMed
11.
Mohd Suzairi MS, Tan SC, Ahmad Aizat AA, Mohd Aminudin M, Siti Nurfatimah MS, Andee ZD, et al. The functional −94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. Cancer Epidemiol. 2013;37:634–8.CrossRefPubMed
12.
Lo SS, Chen JH, Wu CW, Lui WY. Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery. 2009;145:280–5.CrossRefPubMed
13.
Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243:47–54.CrossRefPubMed
14.
Riemann K, Becker L, Struwe H, Nückel H, Dührsen U, Alakus H, et al. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B cell chronic lymphocytic leukemia. Pharmacogenet Genomics. 2006;16:783–8.CrossRefPubMed
15.
Lehnerdt GF, Bankfalvi A, Grehl S, Adamzik M, Lang S, Schmid KW, et al. No association of the NF-kappaB1 -94ins/delATTG promoter polymorphism with relapse-free and overall survival in patients with squamous cell carcinomas of the head and neck region. Int J Immunopathol Pharmacol. 2008;21:827–32.PubMed
16.
Li P, Gu J, Yang X, Cai H, Tao J, Yang X, et al. Functional promoter −94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS One. 2013;8:e71604.PubMedCentralCrossRefPubMed
17.
Kopp TI, Friis S, Christensen J, Tjønneland A, Vogel U. Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men. Cancer Genet. 2013.pii: S2210-7762(13)00084-7
18.
Huo ZH, Zhong HJ, Zhu YS, Xing B, Tang H. Roles of functional NFKB1 and β-TrCP insertion/deletion polymorphisms in mRNA expression and epithelial ovarian cancer susceptibility. Genet Mol Res. 2013;12:3435–43.PubMed
19.
Huang D, Yang L, Liu Y, Zhou Y, Guo Y, Pan M, et al. Functional polymorphisms in NFκB1/IκBα predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese. Hum Genet. 2013;132:451–60.CrossRefPubMed
20.
Vangsted AJ, Nielsen KR, Klausen TW, Haukaas E, Tjønneland A, Vogel U. A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma. Br J Haematol. 2012;158:515–8.CrossRefPubMed
21.
Lin CW, Hsieh YS, Hsin CH, Su CW, Lin CH, Wei LH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PLoS One. 2012;7:e35078.PubMedCentralCrossRefPubMed
22.
Fan Y, Yu W, Ye P, Wang H, Wang Z, Meng Q, et al. NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol. 2011;30:241–5.CrossRefPubMed
23.
Zhou B, Qie M, Wang Y, Yan L, Zhang Z, Liang A, et al. Relationship between NFKB1–94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Ann Oncol. 2010;21:506–11.CrossRefPubMed
24.
Tang T, Cui S, Deng X, Gong Z, Jiang G, Wang P, et al. Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol. 2010;29:9–12.CrossRefPubMed
25.
Andersen V, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in NFkB, PXR. LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer. 2010;10:484.PubMedCentralCrossRefPubMed
26.
Zhou B, Rao L, Li Y, Gao L, Wang Y, Chen Y, et al. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett. 2009;275:72–6.CrossRefPubMed
27.
He Y, Zhang H, Yin J, Xie J, Tan X, Liu S, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis. 2009;30:1916–22.PubMedCentralCrossRefPubMed
28.
Burnik FS, Yalçin S. NFKB1–94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy. 2009;55:381–5.CrossRefPubMed
29.
Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther. 2007;45:423–30.CrossRefPubMed
30.
Zou YF, Yuan FL, Feng XL, Tao JH, Ding N, Pan FM, et al. Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Invest. 2011;29:78–85.CrossRefPubMed
31.
Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G, et al. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol. 2007;42:1332–8.CrossRefPubMed
32.
Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features, and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol. 2007;133:859–66.CrossRefPubMed
Metadaten
Titel
NFKB1 -94 insertion/deletion polymorphism and cancer risk: a meta-analysis
verfasst von
Linlin Xu
Shaoyi Huang
Wei Chen
Zhichun Song
Shu Cai
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1672-z

Weitere Artikel der Ausgabe 6/2014

Tumor Biology 6/2014 Zur Ausgabe

Research Article

p16 CDKN2A SNP rs11515 was not associated with head and neck carcinoma

Research Article

Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis

Research Article

Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1

Research Article

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation

Research Article

The association of c.1471G>A genetic polymorphism in XRCC1 gene with lung cancer susceptibility in Chinese Han population

Research Article

Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise